{"nctId":"NCT02709538","briefTitle":"Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)","startDateStruct":{"date":"2016-04"},"conditions":["Perennial Allergic Rhinitis"],"count":601,"armGroups":[{"label":"GSP 301 NS","type":"EXPERIMENTAL","interventionNames":["Drug: GSP 301 NS"]},{"label":"GSP 301 Placebo NS pH 3.7","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: GSP 301 Placebo NS pH 3.7"]},{"label":"GSP 301 Placebo NS pH 7.0","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: GSP 301 Placebo NS pH 7.0"]}],"interventions":[{"name":"GSP 301 NS","otherNames":[]},{"name":"GSP 301 Placebo NS pH 3.7","otherNames":[]},{"name":"GSP 301 Placebo NS pH 7.0","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Aged â‰¥12 years and older inclusive of either sex.\n2. Documented clinical history of PAR (for at least 2 years preceding the Screening Visit \\[Visit 1\\]) and exhibiting a documented positive skin prick test (wheal diameter at least 3 mm greater than negative diluent control wheal) to at least 1 allergen known to induce PAR. Documentation of a positive result within 12 months prior to the Screening Visit (Visit 1) is acceptable.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. History of anaphylaxis and/or other severe local reaction(s) to skin testing.\n3. History of positive test for HIV, Hepatitis B or Hepatitis C infection.\n4. Documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip.\n5. Subjects with an active pulmonary disorder or infection.\n6. Subjects with posterior subcapsular cataracts or glaucoma","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs).","description":"All TEAEs and serious adverse events (SAEs) occurring in the study, in terms of nature, onset, duration, severity, relationship, and outcome were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"203","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":393},"commonTop":["Upper respiratory tract infection","Headache","Nasopharyngitis","Epistaxis","Nasal discomfort"]}}}